Record Details

Atherothrombosis Journal

View Archive Info
 
 
Field Value
 
Title —
НОВЫЕ ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ И АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА В ЛЕЧЕНИИ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ
 
Creator Н. Воробьева М.
Е. Панченко П.
Н. Воробьева М.; Институт клинической кардиологии им. А. Л. Мясникова ФГБУ РКНПК МЗ РФ
Е. Панченко П.; Институт клинической кардиологии им. А. Л. Мясникова ФГБУ РКНПК МЗ РФ
 
Subject —
—
 
Description —
.
 
Publisher «REMEDIUM GROUP» Ltd.
 
Contributor —
—
 
Date 2016-06-03
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
—
 
Format application/pdf
application/pdf
 
Identifier http://www.aterotromboz.ru/jour/article/view/60
10.21518/2307-1109-2013-1-53-65
 
Source Atherothrombosis Journal; № 1 (2013); 53-65
Атеротромбоз; № 1 (2013); 53-65
2307-1109
10.21518/2307-1109-2013-1
 
Language rus
eng
 
Relation http://www.aterotromboz.ru/jour/article/view/60/90
http://www.aterotromboz.ru/jour/article/view/60/91
Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis // Lancet. 2012. №379. Р. 1835–1846.
Spencer F.A., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism // J. Gen Intern. Med. 2006. №21. Р. 722–727.
Christiansen S.C., Cannegieter S.C., Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events // JAMA. 2005. №293. Р. 2352–2361.
Kearon C., Akl E.A., Comerota A.J. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed.: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012. №141. Suppl. Р. e 419S– e 494 S.
Eriksson B.I., Dahl O.E., RosencherN. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial // J. Thromb. Haemost. 2007. №5. Р. 2178–2185.
Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial // Lancet. 2007. №370. Р. 949–956.
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009. № 361. P. 1139–1151.
Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism // N. Engl. J. Med. 2009. №361. Р. 2342–2352.
Turpie A.G., Lassen M.R., Eriksson B.I. et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies // Thromb. Haemost. 2011. №105. Р. 444–453.
Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. №365. Р. 883–891.
Mega J.L., Braunwald E., Wiviott S.D. et al. Rivaroxaban in patients with a recent acute coronary syndrome // N. Engl. J. Med. 2012. №66. Р. 9–19.
Buller H.R., Lensing A.W.A., Prins M.H. et al. A doseranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study // Blood. 2008. №112. Р. 2242–2247.
Agnelli G., Gallus A., Goldhaber S.Z. et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study // Circulation. 2007. №116. Р. 180–187.
Barritt D.W., Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial // Lancet. 1960. №1. Р. 1309–1312.
The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease // N. Engl. J. Med. 2007. №357. Р. 1094–1104.
Brandjes D.P.M., Heijboer H., Buller H.R. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis // N. Engl. J. Med. 1992. №327. Р. 1485–1489.
Fiessinger J.N., Huisman M.V., Davidson B.L. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial // JAMA. 2005. №293. Р. 681–689.
Mueck W., Lensing A.W., Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention // Clin. Pharmacokinet. 2011. №50. Р. 675–686.
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism // N. Engl. J. Med. 2010. №363. Р 2499–2510.
The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism // N. Engl. J. Med. 2012. №366. Р. 1287–1297.
Schafer A.I. Venous thrombosis as a chronic disease // N. Engl. J. Med. 1999. №340. Р. 955–956.
Prandoni P., Lensing A.W., Cogo A. et al. The longterm clinical course of acute deep venous thrombosis //Ann. Intern. Med. 1996. №125. Р. 1–7.
Schulman S., Rhedin A-S., Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism // N. Engl. J. Med. 1995. №332. Р. 1661–1665.
Agnelli G., Prandoni P., Santamaria M.G. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis // N. Engl. J. Med. 2001. №345. Р. 165–169.
Agnelli G., Prandoni P., Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism // Ann. Intern. Med. 2003. №139. Р. 19–25.
Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism // N. Engl. J. Med. 1999. №340. Р. 901–907.
Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. №365. Р. 981–992.
Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation // N. Engl. J. Med. 2011. №364. Р. 806–817.
Raskob G.E., Gallus A.S., Pineo G.F. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials // J. Bone. Joint Surg. Br. 2012. №94. Р. 257–264.
Agnelli G., Buller H.R., Cohen A. et al. for the AMPLIFY- EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism // N. Engl. J. Med. 2013. №368. Р. 699–708.
Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis // Lancet. 1980. №2. Р. 1328–1329.
Becattini C., Agnelli G., Schenone A. et al. Aspirin for Preventing the Recurrence of Venous Thromboembolism // N. Engl. J. Med. 2012. №366. Р. 1959–1967.
Brighton T.A., Eikelboom J.W., Mann K. et al. Low- Dose Aspirin for Prevention Recurrent Venous Thromboembolism // N. Engl. J. Med. 2012. №367. Р. 1979–1987.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients // BMJ. 1994. №308. Р. 235–246.
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial // Lancet. 2000. №355. Р. 1295–1302.
Grady D., Wenger N.K., Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study // Ann. Intern. Med. 2000. №132. Р. 689–696.
Becattini C., Agnelli G., Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism // Eur. Heart. J. 2005. №26. Р. 77–83.
Patrono C., Baigent C., Hirsh J., Roth G. Antiplate let drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008. №133. Suppl. Р. 199 S–233 S.
Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for with venous thromboembolism: a meta-analysis // Ann. Intern. Med. 2003. №139. Р. 893–900.
Ridker P.M., Goldhaber S.Z., Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism // N. Engl. J. Med. 2003. №348. Р. 1425–1434.
Kearon C., Ginsberg J.S., Kovacs M.J. et al. Comparison of low-intensity warfarin therapy with conventional- intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism // N. Engl. J. Med. 2003. №349. Р. 631–639.
Schulman S., Eriksson H., Goldhaber S.Z. et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism // J. Thromb. Haemost. 2011. №9. Suppl. 2. Р. 731–732.
Schulman S., Baanstra D., Eriksson H. et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism // J. Thromb. Haemost. 2011. №9. Suppl. 2. Р. 22–22.
Воробьева Н.М., Панченко Е.П., Ермолина О.В. и др. Продление терапии эноксапарином до одного месяца способствует реканализации окклюзивно тромбированных глубоких вен // Терапевтический архив. 2011. Т. 83. №8. С. 33–37.
Воробьева Н.М., Панченко Е.П., Добровольский А.Б. [и др.] Независимые предикторы рецидива тромбоза глубоких вен (результаты проспективного 18-месячного наблюдения) // Кардиология. 2010. Т. 50. №12. С. 52–58.
 
Rights Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).